^
    Back
    Association details:
    Biomarker:MET exon 14 mutation
    Cancer:Lung Adenocarcinoma
    Drug:Tepmetko (tepotinib) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    TEPMETKO is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymalepithelial transition (MET) exon 14 skipping alterations.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    JTO Clinical and Research Reports
    Title:

    Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in A Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report

    Published date:
    12/21/2020
    Excerpt:
    A 75-year-old Japanese female never-smoker was presented with a small lung 66 nodule in the right upper lobe...sequencing analysis of the 79 biopsy specimens with FoundationOne®CDx and it revealed a MET exon 14 skipping mutation...We administered tepotinib at a low starting dose of 250mg once daily under careful observation. After 7 weeks, we confirmed efficacy with shrinkage of the enlarged lymph nodes...
    DOI:
    https://doi.org/10.1016/j.jtocrr.2021.100271
    Test:
    FoundationOne® CDx
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Cold Spring Harb Mol Case Stud
    Title:

    Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report

    Published date:
    12/17/2020
    Excerpt:
    …we report a case of a patient with metastatic lung adenocarcinoma harboring a MET exon 14 splice site mutation...he was then enrolled in a clinical trial of tepotinib and continues with stable disease for more than 45 cycles and 31 mo.
    DOI:
    10.1101/mcs.a005785